SCHEMBL905493

SCHEMBL905493

C[C@H](CCC(=O)NCCC[N+](C)(C)CCC(O)S(=O)(=O)[O-])[C@H]1CCC2C3CCC4CCCC[C@]4(C)C3CC[C@@]21C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHA2 P29317 3/20 0.65
GPBAR1 Q8TDU6 8/20 0.56
AKR1B10 O60218 1/20 0.56
AKR1B1 P15121 1/20 0.56
EFNA1 P20827 1/20 0.56
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56
PSENEN Q9NZ42 1/20 0.56
MEN1 O00255 1/20 0.56
LMNA P02545 1/20 0.56
KMT2A Q03164 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
NR1H4 Q96RI1 1/20 0.54
ABCC4 O15439 3/20 0.54
VDR P11473 2/20 0.54
CA1 P00915 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6065533 0.93 EPHA2 (0.66) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
SCHEMBL58082 0.91 EPHA2 (0.67) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
SCHEMBL18045259 0.91 EPHA2 (0.67) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
Sulfuric Acid SCHEMBL2285700 0.91 EPHA2 (0.67) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
SCHEMBL4777980 0.91 EPHA2 (0.67) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
Water SCHEMBL8333417 0.90 EPHA2 (0.66) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
Water SCHEMBL278724 0.90 EPHA2 (0.66) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
SCHEMBL5820770 0.89 EPHA2 (0.66) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
Sulfuric Acid SCHEMBL5587293 0.89 EPHA2 (0.68) EPHA2GPBAR1AKR1B10AKR1B1EFNA1
SCHEMBL55596 0.89 EPHA2 (0.68) EPHA2GPBAR1AKR1B10AKR1B1EFNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150174209-A1 INSULIN-PRAMLINTIDE COMPOSITIONS AND METHODS FOR MAKING AND USING THEM AMYLIN PHARMACEUTICALS. LLC (US) 2015-06-25 US claimed
WO-2013177565-A1 INSULIN-PRAMLINTIDE COMPOSITIONS AND METHODS FOR MAKING AND USING THEM AMYLIN PHARMACEUTICALS, LLC (US) 2013-11-28 WO claimed
US-7312196-B2 Formulations for amylin agonist peptides AMYLIN PHARMACEUTICALS, INC. (US) 2007-12-25 US claimed
US-7160689-B2 Pretreatment instrument of saliva and pretreatment method of saliva GC CORPORATION (JP) 2007-01-09 US claimed
EP-1396726-B1 Pretreatment kit for saliva and pretreatment method for saliva for determination of Mutans streptococci via immunochromatography G C DENTAL IND CORP (JP) 2006-05-24 EP claimed
EP-1271124-B1 Pretreatment instrument of saliva and pretreatment method of saliva G C DENTAL IND CORP (JP) 2006-03-22 EP claimed
US-6897037-B2 Pre-treatment kit for saliva and pre-treatment method for saliva using the same GC CORPORATION (JP) 2005-05-24 US claimed
EP-1248106-B1 Pre-treatment kit for saliva and pre-treatment method for saliva using the same G C DENTAL IND CORP (JP) 2004-06-02 EP claimed
US-20030203423-A1 Pre-treatment kit for saliva and pre-treatment method for saliva using the same GC CORPORATION (JP) 2003-10-30 US claimed
EP-1271124-A1 Pretreatment instrument of saliva and pretreatment method of saliva GC Corporation (JP) 2003-01-02 EP claimed
US-20020197738-A1 Pretreatment instrument of saliva and pretreatment method of saliva GC CORPORATION (JP) 2002-12-26 US claimed
EP-1248106-A1 Pre-treatment kit for saliva and pre-treatment method for saliva using the same GC Corporation (JP) 2002-10-09 EP claimed
US-20240192707-A1 MICROFLUIDIC SYSTEM THE UNIVERSITY OF CHICAGO 2024-06-13 US disclosed
US-20240160231-A1 MICROFLUIDIC SYSTEM THE UNIVERSITY OF CHICAGO 2024-05-16 US disclosed
US-11853087-B2 Microfluidic system THE UNIVERSITY OF CHICAGO (US) 2023-12-26 US disclosed
EP-3290921-B1 DEVICE AND METHOD FOR PRESSURE-DRIVEN PLUG TRANSPORT AND REACTION UNIV CHICAGO (US) 2022-06-15 EP disclosed
EP-1248106-A1 Pre-treatment kit for saliva and pre-treatment method for saliva using the same GC Corporation (JP) 2002-10-09 EP disclosed
US-20020137135-A1 Novel NPG-1 gene that is differentially expressed in prostate tumors BETH ISRAEL DEACONESS MEDICAL CENTER, INC., A MASSACHUSETTS CORPORATION 2002-09-26 US disclosed
WO-2002057789-A2 TEST FOR TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ENFER TECHNOLOGY LIMITED (IE) 2002-07-25 WO disclosed
US-6287777-B1 SEVERAL GENES EXPRESSED DIFFERENTIALLY BETWEEN THE HUMAN PROSTATE CARCINOMA CELL LINES LNCAP AND PC-3, WHICH ARE ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT, RESPECTIVELY, HAVE NOW BEEN ISOLATED. ONE OF THESE GENES, DESIGNATED NPG-1. BETH ISRAEL DEACONESS MEDICAL CENTER 2001-09-11 US disclosed